Company Overview and News

 
Eye On Stock: Sino Hua-An Int’l

10h thestar.com.my
SINO Hua-An International Bhd (code: 2739), which has seen its share price slip since January this year, is facing a long uphill battle to return to a bullish outlook.
2739

2
KLCI pares loss, moves above 1,730 level

2018-10-19 theedgemarkets
KUALA LUMPUR (Oct 19): The FBM KLCI pared some of its loss at the midday break and moved above the 1,730-point level.
7084 4065 7113 TPGVF BATS 4162 1163 9334 6033 5199 TGLVY 2038 5216 PNADF 2739 HIPEF PNAGF GEBHF MSCI

 
KLCI pares gains, struggles to breach 1,800 level

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 8): The FBM KLCI pared some of its gains at mid-morning today, struggling to breach the 1,800-point level.
PBLOF BATS 4162 7087 7043 1295 5168 5014 5007 KLKBY 5029 2445 2542 5225 3867 5517 7668 2739 MYPRY 2836 Q0F IHHHF HRGHY

 
KLCI rises 0.43% as index-linked blue chips lift

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.43% at the midday break today as index-linked blue chip stocks lifted the local benchmark index.
HLFBF 7062 7052 7060 7036 1082 5681 BATS 4162 5014 6033 4634 1783 5029 PNADF 5347 5016 1589 SGPBY TNABY 2739 MYPRY TNABF PNAGF

 
KLCI gains 0.39%, tracks regional markets

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.39% at mid-morning today, lifted by index-linked blue chips and tracking the steady regional markets.
7052 7036 5681 BATS 4162 3034 1481 5014 6033 0152 1783 PNADF 5225 SGPBY 5209 2216 2739 MYPRY Q0F IHHHF PNAGF

 
KLCI remains subdued, tracks regional peers

2018-07-30 theedgemarkets
KUALA LUMPUR (July 30): The FBM KLCI remained subdued at the midday break today, tracking its regional peers.
HLFBF APEXF 7090 8621 7036 BATS 4162 5014 5029 3026 5225 3867 1589 2739 IHHHF PNAGF 1082 5681 6033 5139 PNADF 0900 MYPRY Q0F 3719

 
KLCI struggles to climb higher as sentiment stays tepid

2018-07-30 theedgemarkets
KUALA LUMPUR (July 30): The FBM KLCI struggled to climb higher at mid-morning today as sentiment at the local bourse stayed tepid in line with regional markets.
7113 7036 BATS TPGVF 4162 DKSHY 5029 3026 5225 3867 7722 2739 IHHHF PNAGF 5908 5681 6033 7123 TGLVY PNADF 2542 1899 Q0F 3719 DKSHF

 
Sino Hua-An down 22% on plunge in 2Q earnings

2018-07-30 theedgemarkets
KUALA LUMPUR (July 30): Shares of Sino Hua-An International Bhd, which soared more than tenfold over the past year from 3.5 sen, fell as much as 22.22% earlier this morning to as low as 28 sen after reporting an 88% plunge in net profit for the second quarter ended June 30, 2018 to RM2.53 million last Friday (July 27).
2739 BSMAF 1818

 
KLCI drifts lower in line with region, key blue chips weigh

2018-07-30 theedgemarkets
KUALA LUMPUR (July 30): The FBM KLCI drifted lower in early trade today against the backdrop of cautious regional markets, weighed by index-linked blue chips.
PBLOF 7113 TPGVF 1295 TGLVY 5347 5225 3867 TNABY 2739 TNABF Q0F IHHHF

1
Sino Hua-An’s 2Q net profit falls 88% on lower average selling prices

2018-07-27 theedgemarkets - 1
KUALA LUMPUR (July 27): Sino Hua-An International Bhd’s net profit for the second quarter ended June 30, 2018 (2QFY18) dipped 88% to RM2.53 million from RM21.99 million a year ago due to lower average selling prices of metallurgical coke as well as relatively lower sales volume.
2739

 
KLCI pares loss, remains above 1,760-level

2018-07-27 theedgemarkets
KUALA LUMPUR (July 27): The FBM KLCI dipped 0.25% at midday break but pared its losses to stay above the 1,760-point level.
9385 4065 7113 TPGVF BATS 4162 5246 5202 ORHLF 7277 7123 4006 TGLVY 2739 2836 GEBHF 3719

 
KLCI down marginal 0.22%, hovers above 1,760-level

2018-07-27 theedgemarkets
KUALA LUMPUR (July 27): The FBM KLCI was down marginally at mid-morning, tracking losses at regional markets.
9385 GMALF 4065 7113 TPGVF BATS 4162 5202 7123 CIMDF GMALY TGLVY KLKBY 1023 2445 5347 2542 4715 TNABY 4723 2739 TNABF 3719

 
KLCI remains muted despite uptrend at regional markets

2018-07-25 theedgemarkets
KUALA LUMPUR (July 25): The FBM KLCI clawed into positive territory at mid-morning but remained somewhat muted against the backdrop of the positive regional markets.
HLFBF 7052 UPBMF 4065 1082 9679 5245 2089 5255 5436 1201 3301 8613 2739 2836

 
KLCI rises 0.24%, tracks regional gains

2018-07-24 theedgemarkets
KUALA LUMPUR (July 24): The FBM KLCI rose 0.24% at mid-morning today, tracking regional gains, lifted by select blue chips.
PNADF 3867 1589 7060 4065 7323 2739 PNAGF 6033 9334

 
KLCI drifts lower, tracks losses at regional markets

2018-07-16 theedgemarkets
KUALA LUMPUR (July 16): The FBM KLCI drifted lower at mid-morning today, tracking losses at most regional markets.
HLFBF 7052 UPBMF 1082 5681 BATS 4162 2291 5202 7153 5168 2089 7277 KLKBY 2445 4588 3867 2739 2836 HRGHY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...